European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics

J. P. Thyssen; C. Vestergaard; S. Barbarot; M. S. de Bruin-Weller; T. Bieber; A. Taieb; J. Seneschal; M. J. Cork; C. Paul; C. Flohr; S. Weidinger; M. Trzeciak; T. Werfel; A. Heratizadeh; U. Darsow; D. Simon; A. Torrelo; P. V. Chernyshov; J. F. Stalder; C. Gelmetti; Z. Szalai; Svensson; L. B. von Kobyletzki; L. De Raeve; R. Fölster-Holst; S. Christen-Zaech; D. J. Hijnen; U. Gieler; J. Gutermuth; C. Bangert; P. I. Spuls; B. Kunz; J. Ring; A. Wollenberg; M. Deleuran

doi:10.1111/jdv.17167

European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics

J. P. Thyssen, C. Vestergaard, S. Barbarot, M. S. de Bruin-Weller, T. Bieber, A. Taieb, J. Seneschal, M. J. Cork, C. Paul, C. Flohr, S. Weidinger, M. Trzeciak, T. Werfel, A. Heratizadeh, U. Darsow, D. Simon, A. Torrelo, P. V. Chernyshov, J. F. Stalder, C. GelmettiZ. Szalai, Svensson, L. B. von Kobyletzki, L. De Raeve, R. Fölster-Holst, S. Christen-Zaech, D. J. Hijnen, U. Gieler, J. Gutermuth, C. Bangert, P. I. Spuls, B. Kunz, J. Ring, A. Wollenberg, M. Deleuran

Research output: Contribution to journal › Letter › peer-review

31 Scopus citations

Original language	English
Pages (from-to)	e308-e311
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	35
Issue number	5
DOIs	https://doi.org/10.1111/jdv.17167
State	Published - May 2021

Access to Document

10.1111/jdv.17167

Cite this

Thyssen, J. P., Vestergaard, C., Barbarot, S., de Bruin-Weller, M. S., Bieber, T., Taieb, A., Seneschal, J., Cork, M. J., Paul, C., Flohr, C., Weidinger, S., Trzeciak, M., Werfel, T., Heratizadeh, A., Darsow, U., Simon, D., Torrelo, A., Chernyshov, P. V., Stalder, J. F., ... Deleuran, M. (2021). European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 35(5), e308-e311. https://doi.org/10.1111/jdv.17167

@article{83b1cdb7ab24450897c691a52d4270c9,

title = "European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics",

author = "Thyssen, {J. P.} and C. Vestergaard and S. Barbarot and {de Bruin-Weller}, {M. S.} and T. Bieber and A. Taieb and J. Seneschal and Cork, {M. J.} and C. Paul and C. Flohr and S. Weidinger and M. Trzeciak and T. Werfel and A. Heratizadeh and U. Darsow and D. Simon and A. Torrelo and Chernyshov, {P. V.} and Stalder, {J. F.} and C. Gelmetti and Z. Szalai and Svensson and {von Kobyletzki}, {L. B.} and {De Raeve}, L. and R. F{\"o}lster-Holst and S. Christen-Zaech and Hijnen, {D. J.} and U. Gieler and J. Gutermuth and C. Bangert and Spuls, {P. I.} and B. Kunz and J. Ring and A. Wollenberg and M. Deleuran",

note = "Funding Information: We thank Dr. Karin Lor{\'e}, Division of Immunology and Allergy, Karolinska Institute, Stockholm, Sweden, for her kind review of this article. Funding Information: Dr. Thyssen has attended advisory boards for Eli Lilly, Regeneron, Pfizer, LEO Pharma, Abbvie and Sanofi‐Genzyme, received speaker honorarium from LEO Pharma, Abbvie, Regeneron and Sanofi‐Genzyme, and received research grants from Regeneron and Sanofi‐Genzyme. Dr. Vestergaard has been investigator, speaker or consultant for Novartis, Abbvie, Sanofi, Leo Pharma and Eli Lilly. Dr Barbarot has been a principal investigator, advisory board member or consultant for Pierre Fabre Laboratory, Bioderma, Laboratoire La Roche Posay, Sanofi‐Genzyme, Abbvie, Novartis, Janssen, Leo Pharma, Pfizer, Amgen, Lilly. Dr. de Bruin‐Weller has been a consultant, advisory board member and/or speaker for AbbVie, Almirall, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron and Sanofi‐Genzym. Dr. Bieber has been a principal investigator, advisory board member or consultant for Regeneron, Sanofi, GSK, Celgene, Abbvie, AnaptysBio, MedImmune, Chugai, Pierre Fabre, Novartis, Asana Biosciences, LEO, Galapagos/MorphoSys, BioVerSys, Galderma, Kymab, Glenmark, Astellas, Daiichi‐Sankyo, Lilly, Pfizer, MenloTx, Dermavant and Allmiral. Dr. T. Bieber was speaker, and/or consultant and/or Investigator for AbbVie, Allmiral, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVerSys, B{\"o}hringer‐Ingelheim, Celgene, Daichi‐Sankyo, Dermavant/Roivant, DermTreat, DS Pharma, RAPT/FLX Bio, Galapagos/MorphoSys, Galderma, Glenmark, GSK, Incyte, Kymab, LEO, Lilly, L´Or{\'e}al, MenloTx, Novartis, Pfizer, Pierre Fabre, Sanofi/Regeneron, UCB. T. Bieber is founder of the non‐profit biotech company {\textquoteleft}Davos Biosciences{\textquoteright}. Dr. Gutermuth has been a consultant, advisory board member and/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron and Sanofi‐Genzyme. Dr Ta{\"i}eb has been consultant or investigator for Pierre Fabre, Galderma, Novartis, Johnson and Johnson, Incyte, Abbvie, Modilac, Pfizer, Lilly, Arena, Bioderma and Sanofi. Dr. Seneschal has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, Leo Pharma and Eli Lilly. Dr. Weidinger has received institutional research grants from LEO Pharma and L'Oreal, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Incyte, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Regeneron, LEO Pharma, Abbvie and Galderma, and is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of atopic dermatitis. Dr. Trzeciak has been a speaker, consultant, investigator or advisory board member for LEO Pharma, Pierre Fabre, Pfizer, La Roche Posay, Sanofi‐Genzyme, Novartis, Bioderma and Mead Johnson. Dr. Cork is an Investigator and/or consultant Consultant for Regeneron, Sanofi‐Genzyme, Pfizer, LEO, Galapagos, Novartis, Boots, L'Oreal, Reckitt Benckiser, Oxagen, Johnson&Johnson, Hyphens, Kymab, Astellas, Galderma, Procter&Gamble, Abbvie, Lilly, Galderma, Menlo and Perrigo. Dr. Paul has received grants and been consultant for Allmiral, Amgen, Abbvie, Boehringer, Celgene, Eli Lilly & Co, Novartis, Janssen, Pfizer, LEO Pharma, Merck, UCB pharma, Pierre Fabre, Regeneron and Sanofi‐Genzyme. Dr. Flohr is chief investigator of the UK National Institute for Health Research‐funded TREAT (ISRCTN15837754) and SOFTER (Clinicaltrials.gov: NCT03270566) trials as well as the UK‐Irish Atopic eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and a principal investigator in the European Union Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). His department has also received investigator‐led funding from Sanofi‐Genzyme. Dr. Heratizadeh reports personal fees from Leo Pharma, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Sanofi‐Genzyme, personal fees from Beiersdorf, personal fees from Hans Karrer, personal fees from Nutricia, personal fees from Meda, personal fees from Lilly, grants from Janssen, outside the submitted work. Dr. Darsow gave advice to or received an honorarium for talks or research grant from the following companies: ALK‐Abello, Bencard, Meda, Novartis and Sanofi‐Regeneron outside the submitted work. Dr. Simon has been an investigator, advisory board member, or consultant for AbbVie, AstraZeneca, Galderma, Lilly, Pfizer, Roche Pharma, and Sanofi‐Genzyme. Dr. Torrelo has acted as advisor and/or participant in clinical trials for Sanofi, Lilly, Pfizer, Abbvie and Mylan. Dr. Gelmetti has acted as advisor and/or participant in clinical trials for: Bayer, Sanofi/Regeneron, Galderma and has lectured at educational events sponsored by Pfizer and Leo Pharma. Dr Szalai has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Novartis, has lectured at educational events sponsored by Nutricia, is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Dr. von Kobyletzki has been investigator, speaker, or consultant for Pfizer, Sanofi, Leo Pharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non‐financial support from LEO Pharma, Pierre Fabre, Sanofi‐Genzyme and Bioderma. Dr. F{\"o}lster‐Holst reports being consultant/Advisor for Beiersdorf AG, Johnson&Johnson, LEO Pharma, Neubourg, Novartis Pharma AG, Nutricia, Pfizer Inc., Regeneron, Sanofi‐Aventis as well as speaker for Beiersdorf AG, LEO Pharma, Neubourg, Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer, Procter&Gamble, Regeneron and Sanofi‐Aventis. Dr Christen‐Zaechs has been an advisor, speaker or investigator for Galderma, L'Oreal, La Roche Posey, Pierre Fabre, Procter and Gamble and Sanofi‐Genzyme. Dr. Hijnen has been investigator, speaker, or consultant for Abbvie, Eli Lilly, Incyte, Leo Pharma, MedImmune/Astrazeneca, Pfizer, Sanofi and Thermo Fisher. Dr. Gieler has received institutional research grants from Galderma, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Abbvie, Novartis, Sebamed and Galderma, and is involved in the organization of atopic dermatitis education programmes in Germany for the treatment of atopic dermatitis. Dr. Bangert has been consultant or speaker for Bayer, Mylan, LEO Pharma, Pfizer, Sanofi‐Genzyme, Eli Lilly, Novartis, Celgene and AbbVie and principal investigator for Merck, Novartis, Sanofi, Abbvie, Elli Lilly and Galderma. Dr. Spuls has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), received departmental independent research grants from pharmaceutical industries different since December 2019 for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigator of the SECURE‐AD registry. Dr. Ring has been an advisor or speaker for AbbVie, Allergika, Sanofi‐Genzyme, Pfizer, Bencard, LEO Pharma and Mylan. Dr. Wollenberg has been a principal investigator, advisory board member, or consultant for AbbVie, Almirall, Galderma, Hans Karrer, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi‐Genzyme, and received speaker honoraria from Chugai, Galderma, LEO Pharma, Lilly, Loreal, MedImmune, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc. and Sanofi‐Genzyme. Dr. Deleuran has been a principal investigator, speaker, advisory board member, and/or consultant for LEO Pharma, AbbVie, Almirall, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi‐Genzyme and Pierre Fabre. This research was performed independently through the authors' academic university and hospital affiliations. Dr. Chernyshov, Dr. Stalder, Dr. Svensson, Dr. Kunz reports no conflict of interest.",

year = "2021",

month = may,

doi = "10.1111/jdv.17167",

language = "English",

volume = "35",

pages = "e308--e311",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

Thyssen, JP, Vestergaard, C, Barbarot, S, de Bruin-Weller, MS, Bieber, T, Taieb, A, Seneschal, J, Cork, MJ, Paul, C, Flohr, C, Weidinger, S, Trzeciak, M, Werfel, T, Heratizadeh, A, Darsow, U, Simon, D, Torrelo, A, Chernyshov, PV, Stalder, JF, Gelmetti, C, Szalai, Z, Svensson, von Kobyletzki, LB, De Raeve, L, Fölster-Holst, R, Christen-Zaech, S, Hijnen, DJ, Gieler, U, Gutermuth, J, Bangert, C, Spuls, PI, Kunz, B, Ring, J, Wollenberg, A & Deleuran, M 2021, 'European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics', Journal of the European Academy of Dermatology and Venereology, vol. 35, no. 5, pp. e308-e311. https://doi.org/10.1111/jdv.17167

European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. / Thyssen, J. P.; Vestergaard, C.; Barbarot, S. et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 35, No. 5, 05.2021, p. e308-e311.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - European Task Force on Atopic Dermatitis

T2 - position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics

AU - Thyssen, J. P.

AU - Vestergaard, C.

AU - Barbarot, S.

AU - de Bruin-Weller, M. S.

AU - Bieber, T.

AU - Taieb, A.

AU - Seneschal, J.

AU - Cork, M. J.

AU - Paul, C.

AU - Flohr, C.

AU - Weidinger, S.

AU - Trzeciak, M.

AU - Werfel, T.

AU - Heratizadeh, A.

AU - Darsow, U.

AU - Simon, D.

AU - Torrelo, A.

AU - Chernyshov, P. V.

AU - Stalder, J. F.

AU - Gelmetti, C.

AU - Szalai, Z.

AU - Svensson,

AU - von Kobyletzki, L. B.

AU - De Raeve, L.

AU - Fölster-Holst, R.

AU - Christen-Zaech, S.

AU - Hijnen, D. J.

AU - Gieler, U.

AU - Gutermuth, J.

AU - Bangert, C.

AU - Spuls, P. I.

AU - Kunz, B.

AU - Ring, J.

AU - Wollenberg, A.

AU - Deleuran, M.

N1 - Funding Information: We thank Dr. Karin Loré, Division of Immunology and Allergy, Karolinska Institute, Stockholm, Sweden, for her kind review of this article. Funding Information: Dr. Thyssen has attended advisory boards for Eli Lilly, Regeneron, Pfizer, LEO Pharma, Abbvie and Sanofi‐Genzyme, received speaker honorarium from LEO Pharma, Abbvie, Regeneron and Sanofi‐Genzyme, and received research grants from Regeneron and Sanofi‐Genzyme. Dr. Vestergaard has been investigator, speaker or consultant for Novartis, Abbvie, Sanofi, Leo Pharma and Eli Lilly. Dr Barbarot has been a principal investigator, advisory board member or consultant for Pierre Fabre Laboratory, Bioderma, Laboratoire La Roche Posay, Sanofi‐Genzyme, Abbvie, Novartis, Janssen, Leo Pharma, Pfizer, Amgen, Lilly. Dr. de Bruin‐Weller has been a consultant, advisory board member and/or speaker for AbbVie, Almirall, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron and Sanofi‐Genzym. Dr. Bieber has been a principal investigator, advisory board member or consultant for Regeneron, Sanofi, GSK, Celgene, Abbvie, AnaptysBio, MedImmune, Chugai, Pierre Fabre, Novartis, Asana Biosciences, LEO, Galapagos/MorphoSys, BioVerSys, Galderma, Kymab, Glenmark, Astellas, Daiichi‐Sankyo, Lilly, Pfizer, MenloTx, Dermavant and Allmiral. Dr. T. Bieber was speaker, and/or consultant and/or Investigator for AbbVie, Allmiral, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVerSys, Böhringer‐Ingelheim, Celgene, Daichi‐Sankyo, Dermavant/Roivant, DermTreat, DS Pharma, RAPT/FLX Bio, Galapagos/MorphoSys, Galderma, Glenmark, GSK, Incyte, Kymab, LEO, Lilly, L´Oréal, MenloTx, Novartis, Pfizer, Pierre Fabre, Sanofi/Regeneron, UCB. T. Bieber is founder of the non‐profit biotech company ‘Davos Biosciences’. Dr. Gutermuth has been a consultant, advisory board member and/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron and Sanofi‐Genzyme. Dr Taïeb has been consultant or investigator for Pierre Fabre, Galderma, Novartis, Johnson and Johnson, Incyte, Abbvie, Modilac, Pfizer, Lilly, Arena, Bioderma and Sanofi. Dr. Seneschal has been investigator, speaker, or consultant for Novartis, Abbvie, Sanofi, Leo Pharma and Eli Lilly. Dr. Weidinger has received institutional research grants from LEO Pharma and L'Oreal, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Incyte, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Regeneron, LEO Pharma, Abbvie and Galderma, and is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of atopic dermatitis. Dr. Trzeciak has been a speaker, consultant, investigator or advisory board member for LEO Pharma, Pierre Fabre, Pfizer, La Roche Posay, Sanofi‐Genzyme, Novartis, Bioderma and Mead Johnson. Dr. Cork is an Investigator and/or consultant Consultant for Regeneron, Sanofi‐Genzyme, Pfizer, LEO, Galapagos, Novartis, Boots, L'Oreal, Reckitt Benckiser, Oxagen, Johnson&Johnson, Hyphens, Kymab, Astellas, Galderma, Procter&Gamble, Abbvie, Lilly, Galderma, Menlo and Perrigo. Dr. Paul has received grants and been consultant for Allmiral, Amgen, Abbvie, Boehringer, Celgene, Eli Lilly & Co, Novartis, Janssen, Pfizer, LEO Pharma, Merck, UCB pharma, Pierre Fabre, Regeneron and Sanofi‐Genzyme. Dr. Flohr is chief investigator of the UK National Institute for Health Research‐funded TREAT (ISRCTN15837754) and SOFTER (Clinicaltrials.gov: NCT03270566) trials as well as the UK‐Irish Atopic eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and a principal investigator in the European Union Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). His department has also received investigator‐led funding from Sanofi‐Genzyme. Dr. Heratizadeh reports personal fees from Leo Pharma, personal fees from Novartis, personal fees from Pierre Fabre, personal fees from Sanofi‐Genzyme, personal fees from Beiersdorf, personal fees from Hans Karrer, personal fees from Nutricia, personal fees from Meda, personal fees from Lilly, grants from Janssen, outside the submitted work. Dr. Darsow gave advice to or received an honorarium for talks or research grant from the following companies: ALK‐Abello, Bencard, Meda, Novartis and Sanofi‐Regeneron outside the submitted work. Dr. Simon has been an investigator, advisory board member, or consultant for AbbVie, AstraZeneca, Galderma, Lilly, Pfizer, Roche Pharma, and Sanofi‐Genzyme. Dr. Torrelo has acted as advisor and/or participant in clinical trials for Sanofi, Lilly, Pfizer, Abbvie and Mylan. Dr. Gelmetti has acted as advisor and/or participant in clinical trials for: Bayer, Sanofi/Regeneron, Galderma and has lectured at educational events sponsored by Pfizer and Leo Pharma. Dr Szalai has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Novartis, has lectured at educational events sponsored by Nutricia, is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Dr. von Kobyletzki has been investigator, speaker, or consultant for Pfizer, Sanofi, Leo Pharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/ or received personal fees and non‐financial support from LEO Pharma, Pierre Fabre, Sanofi‐Genzyme and Bioderma. Dr. Fölster‐Holst reports being consultant/Advisor for Beiersdorf AG, Johnson&Johnson, LEO Pharma, Neubourg, Novartis Pharma AG, Nutricia, Pfizer Inc., Regeneron, Sanofi‐Aventis as well as speaker for Beiersdorf AG, LEO Pharma, Neubourg, Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer, Procter&Gamble, Regeneron and Sanofi‐Aventis. Dr Christen‐Zaechs has been an advisor, speaker or investigator for Galderma, L'Oreal, La Roche Posey, Pierre Fabre, Procter and Gamble and Sanofi‐Genzyme. Dr. Hijnen has been investigator, speaker, or consultant for Abbvie, Eli Lilly, Incyte, Leo Pharma, MedImmune/Astrazeneca, Pfizer, Sanofi and Thermo Fisher. Dr. Gieler has received institutional research grants from Galderma, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Abbvie, Novartis, Sebamed and Galderma, and is involved in the organization of atopic dermatitis education programmes in Germany for the treatment of atopic dermatitis. Dr. Bangert has been consultant or speaker for Bayer, Mylan, LEO Pharma, Pfizer, Sanofi‐Genzyme, Eli Lilly, Novartis, Celgene and AbbVie and principal investigator for Merck, Novartis, Sanofi, Abbvie, Elli Lilly and Galderma. Dr. Spuls has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), received departmental independent research grants from pharmaceutical industries different since December 2019 for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigator of the SECURE‐AD registry. Dr. Ring has been an advisor or speaker for AbbVie, Allergika, Sanofi‐Genzyme, Pfizer, Bencard, LEO Pharma and Mylan. Dr. Wollenberg has been a principal investigator, advisory board member, or consultant for AbbVie, Almirall, Galderma, Hans Karrer, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi‐Genzyme, and received speaker honoraria from Chugai, Galderma, LEO Pharma, Lilly, Loreal, MedImmune, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc. and Sanofi‐Genzyme. Dr. Deleuran has been a principal investigator, speaker, advisory board member, and/or consultant for LEO Pharma, AbbVie, Almirall, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi‐Genzyme and Pierre Fabre. This research was performed independently through the authors' academic university and hospital affiliations. Dr. Chernyshov, Dr. Stalder, Dr. Svensson, Dr. Kunz reports no conflict of interest.

PY - 2021/5

Y1 - 2021/5

UR - http://www.scopus.com/inward/record.url?scp=85102134881&partnerID=8YFLogxK

U2 - 10.1111/jdv.17167

DO - 10.1111/jdv.17167

M3 - Letter

C2 - 33587756

AN - SCOPUS:85102134881

SN - 0926-9959

VL - 35

SP - e308-e311

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 5

ER -

Thyssen JP, Vestergaard C, Barbarot S, de Bruin-Weller MS, Bieber T, Taieb A et al. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology. 2021 May;35(5):e308-e311. doi: 10.1111/jdv.17167

European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics

Access to Document

Other files and links

Cite this